Mostrando 2 resultados de: 2
Filtros aplicados
Publisher
Frontiers in Oncology(2)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(2)
ODS 17: Alianzas para lograr los objetivos(2)
ODS 3: Salud y bienestar(2)
Origen
scopus(2)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusNimotuzumab for Patients With Inoperable Cancer of the Head and Neck
ReviewAbstract: EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasisPalabras claves:eGFR, head and neck, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Iznaga-Escobar N., Mazorra Z., Mestre Fernández B., Tania CrombetFuentes:scopus